Program Description

Selective monoamine reuptake inhibition has dominated major depressive disorder (MDD) treatment, yet MDD is complex with many subtypes and contributors. Thus, many treatments, while effective for some, fall short for many others. Traditionally, most patients do not achieve remission with their first antidepressant therapy (ADT) and the likelihood of response decreases with each successive trial. This has prompted the development of agents with novel and multitargeted psychotropic mechanisms in an effort to improve patient outcomes.

This interactive virtual Grand Rounds series uses the collective perspectives of a group of leading psychiatry experts as a tool to help guide the optimal use of these novel therapeutics in clinical decision-making. These expert perspectives, combined with a review of modern literature regarding how and for whom they may be appropriately integrated into practice, form the basis for this activity.